Literature DB >> 17047893

Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinism.

Lois M Endo1, Steven M Rowe, Robb L Romp, Mark A Buckmaster, T Prescott Atkinson.   

Abstract

Behçet's disease (BD) is a systemic vasculitis that may involve a variety of organs. We describe a girl with oculocutaneous albinism (OCA) who, on initial evaluation for popliteal artery occlusion, was noted to have multiple cardiac thrombi. She later developed hemoptysis, which was the result of bilateral pulmonary artery aneurysms. Her clinical picture was consistent with BD. She was initially treated with prednisone and cyclophosphamide, followed by maintenance therapy with infliximab. This case describes a unique patient with OCA who developed BD with large pulmonary aneurysms and has remained stable for over 1 year while receiving infliximab.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047893     DOI: 10.1007/s10067-006-0426-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 2.  Pulmonary complications of Behçet's disease.

Authors:  Feyza Erkan; Esen Kiyan; Atadan Tunaci
Journal:  Clin Chest Med       Date:  2002-06       Impact factor: 2.878

3.  Treatment with infliximab for a child with Behçet's disease.

Authors:  Frank T Saulsbury; James A Mann
Journal:  Arthritis Rheum       Date:  2003-08-15

4.  Infliximab treatment for severe orogenital ulceration in Behçet's disease.

Authors:  M Connolly; J S Armstrong; D A Buckley
Journal:  Br J Dermatol       Date:  2005-11       Impact factor: 9.302

Review 5.  Behçet's disease and cardiovascular involvement.

Authors:  F Atzeni; P Sarzi-Puttini; A Doria; L Boiardi; N Pipitone; C Salvarani
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 6.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

7.  Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.

Authors:  Ilknur Tugal-Tutkun; Abdulbaki Mudun; Meri Urgancioglu; Sevil Kamali; Esen Kasapoglu; Murat Inanc; Ahmet Gül
Journal:  Arthritis Rheum       Date:  2005-08

8.  Successful treatment of long-standing neuro-Behçet's disease with infliximab.

Authors:  Haroon Sarwar; Hugh McGrath; Luis R Espinoza
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

9.  Childhood Behçet's disease: clinical features and comparison with adult-onset disease.

Authors:  I Krause; Y Uziel; D Guedj; M Mukamel; L Harel; Y Molad; A Weinberger
Journal:  Rheumatology (Oxford)       Date:  1999-05       Impact factor: 7.580

10.  Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.

Authors:  M Leiba; U Seligsohn; Y Sidi; D Harats; B A Sela; J H Griffin; A Livneh; N Rosenberg; I Gelernter; H Gur; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

View more
  3 in total

1.  Is Immunosuppressive and Thrombolytic Therapy Really Effective in a Patient With Intracardiac Thrombosis and Pulmonary Artery Aneurysm due to Behçet's Disease?

Authors:  Nükhet Aladağ Çiftdemir; Selman Gökalp; Tuba Eren
Journal:  Arch Rheumatol       Date:  2019-05-22       Impact factor: 1.472

Review 2.  Adalimumab in the management of Behçet's disease.

Authors:  Atsuhisa Ueda; Mitsuhiro Takeno; Yoshiaki Ishigatsubo
Journal:  Ther Clin Risk Manag       Date:  2015-04-13       Impact factor: 2.423

3.  Behçet's Disease and Intracardiac Thrombosis: A Report of Three Cases.

Authors:  Nurşen Düzgün; Orhan Küçükşahin; Kayhan Çetin Atasoy; Canan Togay Işıkay; Demet Menekşe Gerede; Ayşe Erden; Seda Kaynak Sahap; Muhammed Arif Ibiş; Aşkın Ateş
Journal:  Case Rep Rheumatol       Date:  2013-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.